
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics
Details : Under the licensing agreement, Revio will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 17, 2025
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Revio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
Details : RT001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 24, 2021

RT001 in Amyotrophic Lateral Sclerosis
Details : RT001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 21, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RT001 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 25, 2019
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RT001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
Details : RT001 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neuroaxonal Dystrophies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 27, 2018
Lead Product(s) : RT001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
Details : RT001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 15, 2015
Lead Product(s) : RT001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RT001
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RT001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lateral Canthal Lines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 17, 2010
Lead Product(s) : RT001
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
